Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Diagnosis and Management of Hepatobiliary Pancreatic Disease
share announcement

Diagnosis and Management of Hepatobiliary Pancreatic Disease

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1724

Special Issue Editors

Prof. Dr. José Guilherme Tralhão

E-Mail Website
Guest Editor
Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
Interests: bile duct diseases; liver diseases; pancreas diseases
Dr. Rui Caetano Oliveira

E-Mail Website
Guest Editor
Department of Pathology, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, Portugal
Interests: RNA; human disease; cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Ana Margarida Abrantes

E-Mail Website
Guest Editor
1. Biophysics Institute of Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), University of Coimbra, 3000-354 Coimbra, Portugal
2. Center for Innovative Biomedicine and Biotechnology (CIBB), 3000-354 Coimbra, Portugal
Interests: cancer; biophysics; radiobiology; animal models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Hepatobiliary diseases are a complex group of pathologies, usually associated with high morbidity and mortality. 

These pathologies require multidisciplinary intervention in order to achieve successful intervention. The role of entities is wide, with a spectrum that encompasses malformative diseases, tumoral lesions and inflammatory pathologies than can be approached by medical therapies, radiology procedures or surgical interventions. 

This Special Issue on “Diagnosis and Management of Hepatobiliary Pancreatic Disease” will cover all aspects of hepatobiliary and pancreatic diseases, with a focus on diagnosis, treatment, follow-up and prognosis considering all expertise areas that can contribute to improving clinical approach.  

Prof. Dr. José Guilherme Tralhão
Dr. Rui Caetano Oliveira
Dr. Ana Margarida Abrantes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatobiliary
  • pancreatic
  • diagnostic
  • treatment
  • prognosis
  • biomarkers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 658 KiB  
Article
Tumor Stroma Area and Other Prognostic Factors in Pancreatic Ductal Adenocarcinoma Patients Submitted to Surgery
by Maria João Amaral, Mariana Amaral, João Freitas, Rui Caetano Oliveira, Marco Serôdio, Maria Augusta Cipriano and José Guilherme Tralhão
Diagnostics 2023, 13(4), 655; https://doi.org/10.3390/diagnostics13040655 - 09 Feb 2023
Cited by 1 | Viewed by 1251
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a dense stroma, responsible for up to 80% of its volume. The amount of stroma can be associated with prognosis, although there are discrepancies regarding its concrete impact. The aim of this work was to study prognostic factors [...] Read more.
Pancreatic ductal adenocarcinoma (PDAC) has a dense stroma, responsible for up to 80% of its volume. The amount of stroma can be associated with prognosis, although there are discrepancies regarding its concrete impact. The aim of this work was to study prognostic factors for PDAC patients submitted to surgery, including the prognostic impact of the tumor stroma area (TSA). A retrospective study with PDAC patients submitted for surgical resection was conducted. The TSA was calculated using QuPath-0.2.3 software. Arterial hypertension, diabetes mellitus, and surgical complications Clavien–Dindo>IIIa are independent risk factors for mortality in PDAC patients submitted to surgery. Regarding TSA, using >1.9 × 1011 µ2 as cut-off value for all stages, patients seem to have longer overall survival (OS) (31 vs. 21 months, p = 0.495). For stage II, a TSA > 2 × 1011 µ2 was significantly associated with an R0 resection (p = 0.037). For stage III patients, a TSA > 1.9 × 1011 µ2 was significantly associated with a lower histological grade (p = 0.031), and a TSA > 2E + 11 µ2 was significantly associated with a preoperative AP ≥ 120 U/L (p = 0.009) and a lower preoperative AST (≤35 U/L) (p = 0.004). Patients with PDAC undergoing surgical resection with preoperative CA19.9 > 500 U/L and AST ≥ 100 U/L have an independent higher risk of recurrence. Tumor stroma could have a protective effect in these patients. A larger TSA is associated with an R0 resection in stage II patients and a lower histological grade in stage III patients, which may contribute to a longer OS. Full article
(This article belongs to the Special Issue Diagnosis and Management of Hepatobiliary Pancreatic Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop